Remove 2019 Remove Packaging Remove Pharmaceuticals Remove Regulations
article thumbnail

European Commission vs Big Pharma, or profit vs access?  

Drug Discovery World

The commission is proposing the introduction of temporary emergency marketing authorisations 1. Extra foreign inspections Since July 2019, the MRA (Mutual Recognition Agreement) between the EU and the US FDA has been fully in force. She also does not believe that the problems with Europe’s medicines can be solved with regulation.

article thumbnail

Analysis Life Sciences Thank You What We Expect the FDA to do in August and September 2024

Agency IQ

What We Expect the FDA to do in August and September 2024 In this ongoing feature, AgencyIQ looks at public data to determine what the FDA is likely to do in the months ahead, including key deadlines, meetings, events, planned regulations, comment periods and more.

FDA 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Article Periodic Thank You Commission unveils “one substance, one assessment” reform package

Agency IQ

Commission unveils “one substance, one assessment” reform package The Commission has long aspired to realize its one substance, one assessment concept in the EU’s chemical regulatory regime. With the publication of three proposed legal acts, this concept is one step closer to streamlining the way the bloc regulates chemicals.

article thumbnail

Article EMA Thank You European Commission reveals action plan to address medicines shortages

Agency IQ

Shortages increased by 60% between 2017 and 2019 in select European countries, the U.S., The Pharmaceutical Group of the European Union (PGEU) conducted a survey finding shortages worsened in 2022 compared to 2021, with most European countries reporting worsening. See AgencyIQ’s analysis of the proposed regulation.] wide level.

article thumbnail

Transcending expectations for cell & gene therapy development

Drug Discovery World

As the field matures and the risks are better understood, regulators continue to streamline duplicative and burdensome oversight efforts 5. For regulatory purposes, they may be treated more like a pharmaceutical or a blood product. 2019,January 15). A quality system that is set up to handle both is required. Molecular therapy.

Therapies 130
article thumbnail

Regulatory Submissions for Dengue Vaccine Candidate in EU and Dengue-Endemic Countries

The Pharma Data

Along with the scientific opinion issued by the Committee for Medicinal Products for Human Use (CHMP), national regulators in countries participating in the EU-M4all procedure will conduct their own assessments to determine if national marketing authorizations for TAK-003 are granted. About Dengue.

Vaccine 52
article thumbnail

Analysis Life Sciences Thank You After 13-year review, FDA finalizes ‘clear, conspicuous and neutral’ drug advertising rule

Agency IQ

The regulations also provided clarification regarding what does not constitute a “true statement,” including false or misleading information, failure to reveal important facts, and/or the lack of a fair balance between side effects/contraindications and effectiveness.

FDA 40